BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 10483138)

  • 1. [High-dose chemotherapy with autologous peripheral blood stem cell transplantation support in a patient with breast cancer metastasis to bone marrow: immunocytochemical monitoring of cancer-cell contamination].
    Uno H; Fujita M; Hino N; Nakagawa H; Miyagawa H; Aoki J; Taniyama K; Sasaki N
    Rinsho Ketsueki; 1999 Jul; 40(7):556-62. PubMed ID: 10483138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Combination of high-dose chemotherapy with autologous hematopoietic stem cell transplantation for recurrent and high-risk breast cancer: a pilot study].
    Shi Y; Pan F; Han X
    Zhonghua Yi Xue Za Zhi; 1999 Dec; 79(12):890-3. PubMed ID: 11715500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [CBDCA, etoposide and epirubicin high-dose combination chemotherapy supported by peripheral blood stem cell transplantation (PBSCT) in metastatic breast cancer].
    Suwata J; Takada S; Murata N; Ishizuka N; Idezuki Y; Kobayashi M
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):83-8. PubMed ID: 9987502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support.
    Vredenburgh JJ; Silva O; Broadwater G; Berry D; DeSombre K; Tyer C; Petros WP; Peters WP; Bast RC
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):91-7. PubMed ID: 9267669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab].
    Kanaji N; Ishibashi K; Uno H; Hino N
    Gan To Kagaku Ryoho; 2002 Dec; 29(13):2569-72. PubMed ID: 12506485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer.
    Bilgrami S; Feingold JM; Bona RD; Edwards RL; Khan AM; Rodriguez-Pinero F; Khan IA; Kazierad D; Clive J; Tutschka PJ
    Bone Marrow Transplant; 2000 Jan; 25(2):123-30. PubMed ID: 10673668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
    Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
    J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [High-dose adjuvant chemotherapy with peripheral blood stem cell transplantation for breast cancer with poor prognosis--a pilot study].
    Maruyama F; Ezaki K; Miyazaki H; Wakita M; Maeda H; Nomura T; Tsuzuki M; Sobue R; Okamoto M; Matsui T
    Gan To Kagaku Ryoho; 1992 Sep; 19(11):1859-65. PubMed ID: 1381571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.
    Peppercorn J; Herndon J; Kornblith AB; Peters W; Ahles T; Vredenburgh J; Schwartz G; Shpall E; Hurd DD; Holland J; Winer E
    Cancer; 2005 Oct; 104(8):1580-9. PubMed ID: 16118805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
    Klein JL; Rey PM; Dansey RD; Karanes C; Du W; Abella E; Cassells L; Hamm C; Peters WP; Baynes RD
    Bone Marrow Transplant; 2000 May; 25(10):1047-52. PubMed ID: 10828864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunocytochemical detection of tumor cells in bone marrow and peripheral blood stem cell collections from patients with ovarian cancer.
    Ross AA; Miller GW; Moss TJ; Kahn DG; Warner NE; Sweet DL; Louie KG; Schneidermann E; Pecora AL; Meagher RC
    Bone Marrow Transplant; 1995 Jun; 15(6):929-33. PubMed ID: 7581093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Occult tumor cells detected in autologous blood stem cell harvests have no impact on 5 year outcomes for breast cancer patients with 4-9 positive nodes treated with adjuvant high-dose therapy and stem cell transplantation.
    Reed E; Kessinger A; Murphy B; Tarantolo S; Traystman M; Sharp JG
    Bone Marrow Transplant; 2003 Apr; 31(7):571-4. PubMed ID: 12692623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of tumor cells in the bone marrow of stage IV breast cancer patients receiving high-dose chemotherapy: the role of induction chemotherapy.
    Vredenburgh JJ; Peters WP; Rosner G; DeSombre K; Johnston WW; Kamel A; Wu K; Bast RC
    Bone Marrow Transplant; 1995 Dec; 16(6):815-21. PubMed ID: 8750275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor cell contamination of peripheral blood stem cell transplants and bone marrow in high-risk breast cancer patients.
    Schulze R; Schulze M; Wischnik A; Ehnle S; Doukas K; Behr W; Ehret W; Schlimok G
    Bone Marrow Transplant; 1997 Jun; 19(12):1223-8. PubMed ID: 9208116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma - a phase II study.
    Toh HC; McAfee SL; Sackstein R; Multani P; Cox BF; Garcia-Carbonero R; Colby C; Spitzer TR
    Bone Marrow Transplant; 2000 Jan; 25(1):19-24. PubMed ID: 10654009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose chemotherapy in patients with breast cancer: evaluation of infusing peripheral blood stem cells containing occult tumor cells.
    Weaver CH; Moss T; Schwartzberg LS; Zhen B; West J; Rhinehart S; Campos L; Beeker T; Lautersztain L; Messino M; Buckner CD
    Bone Marrow Transplant; 1998 Jun; 21(11):1117-24. PubMed ID: 9645574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
    Hawkins DS; Felgenhauer J; Park J; Kreissman S; Thomson B; Douglas J; Rowley SD; Gooley T; Sanders JE; Pendergrass TW
    Cancer; 2002 Sep; 95(6):1354-65. PubMed ID: 12216105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of therapy-related leukemia or myelodysplastic syndrome.
    Martínez-Climent JA; Comes AM; Vizcarra E; Benet I; Arbona C; Prósper F; Solano C; García Clavel B; Marugán I; Lluch A; García-Conde J
    Bone Marrow Transplant; 2000 Jun; 25(11):1203-8. PubMed ID: 10849534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outpatient sequential high dose alkylation with stem cell support for patients with advanced breast cancer: a phase I-II study.
    Genre D; Viens P; Gravis G; Bertucci F; Cowen D; Novakovitch G; Derméche S; Chabannon C; Oziel-Taieb S; Camerlo J; Houvenaeghel G; Jacquemier J; Maraninchi D
    Anticancer Res; 2000; 20(3B):2033-40. PubMed ID: 10928147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.